Quantcast

Latest HIV Drug Stories

HIV Antiretroviral Drug Has Psychoactive Effects
2013-04-22 05:22:19

redOrbit Staff & Wire Reports - Your Universe Online The psychoactivity of an antiretroviral (ARV) drug commonly used to treat HIV has been linked to its recreational use, according to research presented during the Experimental Biology 2013 conference in Boston, Massachusetts on Sunday. The medication efavirenz (which is also known under the brand names Sustiva and Stocrin) has become popular as a treatment for the virus that causes AIDS due to its ability to suppress replication of...

2012-06-07 08:49:08

Study finds that HIV receptor CCR5 is induced by oncogenes in breast cancer cells, too The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research. Such drugs target the HIV receptor CCR5, which the virus uses to enter and infect host cells, and has historically only been associated with expression in...

2011-05-03 14:48:15

A widely used HIV drug could be used to prevent cervical cancer caused by infection with the human papilloma virus (HPV), say scientists. University of Manchester researchers, working with colleagues in Canada, have discovered how the antiviral drug lopinavir attacks HPV by switching on a natural viral defence system in infected cells. The study, published in the journal Antiviral Therapy, builds on the team's previous work in 2006 that first identified lopinavir as a potential therapeutic...

2009-10-15 14:07:00

Novel HIV Drug to be Studied in Cell Cultures and in Patients PHILADELPHIA, Oct. 15 /PRNewswire-USNewswire/ -- A $6 million, five-year federal grant to The Children's Hospital of Philadelphia Research Institute will enable researchers to investigate a novel approach in treating HIV infection -- a unique class of drugs focused on developing therapies for psychological and neurological effects in AIDS. Unlike many current HIV treatments, which are combinations of antiretroviral drugs,...

2009-05-28 11:56:36

 Focusing HIV drug development on immune cells called macrophages instead of traditionally targeted T cells could bring us closer to eradicating the disease, according to new research from University of Florida and five other institutions.In the largest study of its kind, researchers found that in diseased cells "” such as cancer cells "” that are also infected with HIV, almost all the virus was packed into macrophages, whose job is to "eat" invading disease agents.What's...

2d99baef686410fd8ad0fed62dc4aae21
2008-10-14 09:30:10

Nature study reveals long-sought atomic structure of key enzyme and suggests new approach for drug development Humans have a built-in weapon against HIV, but until recently no one knew how to unlock its potential. A study published online by the journal Nature reveals the atomic structure of this weapon "“ an enzyme known as APOBEC-3G "“ and suggests new directions for drug development. APOBEC-3G is present in every human cell. It is capable of stopping HIV at the first step of...

2008-07-26 00:00:37

MELVILLE, N.Y. _ A drug that zeros in on a novel HIV target and disables a key link in the infection process can successfully treat patients who have failed other therapies, Stony Brook University doctors have found. Dr. Roy Steigbigel, chief of Stony Brook University Medical Center's HIV program, said there is a new class of anti-viral medications called integrase inhibitors that can "rescue people on a downward curve," those for whom resistance has made treatment difficult. The...

2008-07-08 09:01:11

Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, announced that it has filed an IND (Investigational New Drug) application for SP-6310 in the treatment of HIV-infected patients with abnormal cortisol levels. Following discussions and protocol agreement with U.S. Food and Drug Administration (FDA), Samaritan will conduct an 8-week Phase II clinical study with SP-6310 in...

2008-06-17 09:01:13

NanoViricides has said that its lead anti-HIV drug candidate demonstrated markedly superior survival results in the test animals when compared to those animals given the anti-HIV 'combo cocktail' in a double-blind animal study. The company reported that the best nanoviricide anti-HIV drug candidate improved total hours of survival time by 99% with respect to appropriate controls. In contrast, the combo therapy improved survival hours by only 52%. Furthermore, AZT, the first drug used in...

2006-08-25 04:25:00

LONDON -- A commonly used HIV medicine may also help prevent cervical cancer and could be developed into an anti-cancer cream, early laboratory tests by British scientists suggest. Researchers at the University of Manchester said on Friday that test-tube studies showed the drug lopinavir selectively killed human papilloma virus (HPV) -- the virus that causes cervical cancer -- as well as HIV. Lopinavir belongs to a class of HIV drugs known as protease inhibitors. It is a key component of...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related